The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...

China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for the treatment of the chronic hepatitis D virus infection in adults, the company said on Friday.

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...

Zydus has launched Tishtha, an affordable biosimilar of nivolumab, at nearly one-fourth the original price. Approved by the ...

As cancer cases climb steadily across India, lower-cost biosimilars like Tishtha could reshape access to life-saving ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according ...